{
    "clinical_study": {
        "@rank": "68684", 
        "arm_group": [
            {
                "arm_group_label": "continuous vancomycin infusion", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "intermittent vancomycin infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "vancomycin in this arm will be administered as intermittent infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being carried out to find out whether there is reduction in vancomycin-induced\n      kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous\n      infusion.\n\n      This study will recruit 220 subjects from 2 hospitals over a period of 3 years.\n\n      Participants are invited if they have an infection that requires prolonged vancomycin\n      therapy (> more than 10 days)."
        }, 
        "brief_title": "Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections Requiring Prolonged Duration (>10 Days) of Vancomycin", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults aged 21-80 years\n\n          -  Documented infection requiring prolonged (> 10 days) of vancomycin therapy\n\n          -  Creatinine clearance > 50 ml/min (using Cockroft-Gault equation)\n\n        Exclusion Criteria:\n\n          -  Patient already received 7 days or more of vancomycin therapy\n\n          -  Pregnancy\n\n          -  Severe burns > 40% body surface area\n\n          -  Spinal cord injuries\n\n          -  Participation in another interventional trial in previous 30 days\n\n          -  Inability to obtain informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720940", 
            "org_study_id": "NUHID-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "continuous vancomycin infusion", 
                "description": "24-hour continuous infusion of vancomycin", 
                "intervention_name": "continuous vancomycin infusion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "intermittent vancomycin infusion", 
                "intervention_name": "intermittent vancomycin infusion", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vancomycin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 1, 2012", 
        "location": {
            "contact": {
                "email": "shire_yang_tan@nuhs.edu.sg", 
                "last_name": "Shire Yang Tan", 
                "phone": "97989001"
            }, 
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore"
                }, 
                "name": "National University Hospital"
            }, 
            "investigator": {
                "last_name": "Dale Fisher", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin", 
        "overall_contact": {
            "email": "shire_yang_tan@nuhs.edu.sg", 
            "last_name": "Shire Yang Tan", 
            "phone": "97989001"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Singapore: Domain Specific Review Boards", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "nephrotoxicity as defined by the acute kidney injury network (AKIN) criteria using only serum creatinine criteria", 
            "measure": "nephrotoxicity", 
            "safety_issue": "Yes", 
            "time_frame": "occurring any time while on vancomycin treatment up to 14 days post treatment completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720940"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National University Hospital, Singapore", 
            "investigator_full_name": "Medicine", 
            "investigator_title": "Division of Infectious Diseases", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "serum and urine NGAL and cystatin C", 
            "measure": "biomarkers for detection of early nephrotoxicity", 
            "safety_issue": "No", 
            "time_frame": "measured weekly from the date of randomization until 14 days post completion of vancomycin"
        }, 
        "source": "National University Hospital, Singapore", 
        "sponsors": {
            "collaborator": {
                "agency": "Tan Tock Seng Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National University Hospital, Singapore", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}